A study to assess the effect of Mehamudgarvatika along with Metformin in stool prameha with special reference to Type 2 Diabetes mellitus

A Randomised Controlled Clinical Study to Evaluate the Apatarpana Effect of Mehamudgarvatika as an Adjuvant Drug to Metformin in the Management of Sthool Prameha with Special Reference to Type 2 Diabetes Mellitus - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/109104

Enrollment

Registered

2026-04-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Both genders and age between 30 to 70 years. Subjects who are willing to give informed consent. Patients have sing and symptoms of prameha like swedadhikya,angagavrav,alasya,nidradhikya compared to a control group. Patient having BSL FASTING 126 TO 200 AND POSTPRADIAL 250 TO 350 hBa1C 6.5 TO 8 BMI more than or equal to 25kg per meter square Lipid profile abnormalities(any one or more of the following) Total Cholesterol more than 200 Triglycerides more than 150 LDL more than 100 HDL less than 40 in male or less than 50 in females

Exclusion criteria

Exclusion criteria: Patient taking or requiring OHA other than metformin Patient having IDDM ,Juvenile Diabetes Mellitus, Gestational Diabetes Mellitus, diabetes with complications, Ketoacidosis, Drug induced Diabetes like use of glucocorticoid, thiazide diuretic etc. Patients with BMI less than 25 not considered Sthoola Prameha Pregnant and lactating women Hepatitis B, Hepatitis C, AIDS, Tuberculosis, CA or any other immunocompressive disorder and major life threatening diseases. Patient on immunosuppressive therapy, on antidepressant agents. Mentally retarded, psychologically unstable and non cooperative patients.

Design outcomes

Primary

Measure	Time frame
deacrease in BSL fasting and postprandial and HbA1c levelsTimepoint: deacrease in BSL fasting and postprandial and HbA1c levels	—

Secondary

Measure	Time frame
changes in weight and BMI of the patient before and after the treatmentTimepoint: 12 weeks	—

Countries

India

Contacts

Public ContactDr Sayyad Zishan Sd Yakub

R.A.Podar Govt(Ayu)College ,worli,Mumbai-18

drkadlaskar@gmail.com9422330084

Outcome results